The aim of this study was to investigate the effect of Lactobacillus plantarum HFY09 on gastric injury induced by HCl/ethanol in Kunming mice. The results showed that HFY09-H inhibited any increases in gastric juice volume, maintained the normal pH value of gastric acid, and reduced the damage caused to the gastric mucosa and gastric wall, the inhibition rate on the injury area reaches 63.70%. Compared with the negative control group, HFY09 increased the levels of serum somatostatin (SS) and vasoactive intestinal peptide (VIP), and also decreased the levels of substance P (SP), endothelin-1 (ET-1), interleukin-6 (IL-6), interleukin-12 (IL-12), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ). In addition, real time fluorescent quantitative PCR (Q-PCR) also confirmed that high-dose HFY09 (109 CFU/kg/day) upregulated the mRNA expression of copper/zinc superoxide dismutase (Cu/Zn-SOD), manganese superoxide dismutase (Mn-SOD), catalase (CAT), endothelial nitric oxide synthase (eNOS), and neuronal nitric oxide synthase (nNOS), and downregulated the expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2). At the same time, the results of the HFY09 treatment group were similar to those of the ranitidine treatment group. These results indicate that HFY09 can prevent gastric injury induced by HCl/ethanol in vivo. Therefore, HFY09 may play a potential role in the treatment of gastric diseases.

中文翻译：

---

植物乳杆菌HFY09对HCl /乙醇诱导的小鼠胃损伤的预防作用

这项研究的目的是研究植物乳杆菌HFY09对HCl /乙醇诱导的昆明小鼠胃损伤的影响。结果表明，HFY09-H抑制胃液体积的任何增加，保持胃酸的正常pH值，减少对胃粘膜和胃壁的伤害，对损伤部位的抑制率达到63.70％。与阴性对照组相比，HFY09增加了血清生长抑素（SS）和血管活性肠肽（VIP）的水平，还降低了P物质（SP），内皮素1（ET-1）和白介素6（ IL-6），白介素12（IL-12），肿瘤坏死因子-α（TNF-α）和干扰素-γ（IFN-γ）。此外，实时荧光定量PCR（Q-PCR）还证实了大剂量HFY09（109 CFU / kg / day）上调了铜/锌超氧化物歧化酶（Cu / Zn-SOD），锰超氧化物歧化酶（Mn-SOD）的mRNA表达），过氧化氢酶（CAT），内皮型一氧化氮合酶（eNOS）和神经元一氧化氮合酶（nNOS），并下调诱导型一氧化氮合酶（iNOS）和环氧合酶2（COX-2）的表达。同时，HFY09治疗组的结果与雷尼替丁治疗组的结果相似。这些结果表明，HFY09可以在体内预防由HCl /乙醇引起的胃损伤。因此，HFY09可能在胃病的治疗中发挥潜在作用。内皮一氧化氮合酶（eNOS）和神经元一氧化氮合酶（nNOS），并下调诱导型一氧化氮合酶（iNOS）和环氧合酶2（COX-2）的表达。同时，HFY09治疗组的结果与雷尼替丁治疗组的结果相似。这些结果表明，HFY09可以在体内预防由HCl /乙醇引起的胃损伤。因此，HFY09可能在胃病的治疗中起潜在作用。内皮一氧化氮合酶（eNOS）和神经元一氧化氮合酶（nNOS），并下调诱导型一氧化氮合酶（iNOS）和环氧合酶2（COX-2）的表达。同时，HFY09治疗组的结果与雷尼替丁治疗组的结果相似。这些结果表明，HFY09可以在体内预防由HCl /乙醇引起的胃损伤。因此，HFY09可能在胃病的治疗中起潜在作用。